Man Group’s G1 Therapeutics GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-127,723
Closed -$291K – 2276
2024
Q2
$291K Sell
127,723
-147,635
-54% -$564K ﹤0.01% 1790
2024
Q1
$1.19M Buy
275,358
+128,692
+88% +$448K ﹤0.01% 1481
2023
Q4
$447K Buy
+146,666
New +$276K ﹤0.01% 1713
2023
Q1
– Sell
-23,760
Closed -$114K – 1912
2022
Q4
$129K Buy
+23,760
New +$199K ﹤0.01% 1863
2021
Q2
– Sell
-11,700
Closed -$282K – 2121
2021
Q1
$282K Sell
11,700
-85,049
-88% -$1.98M ﹤0.01% 1650
2020
Q4
$1.74M Buy
96,749
+33,200
+52% +$496K 0.01% 1250
2020
Q3
$734K Buy
+63,549
New +$1.05M ﹤0.01% 1453

Man Group's GTHX Position: Q3 2024 in Review

Man Group sold out of G1 Therapeutics (GTHX) in Q3 2024, closing a stake of 127,723 shares — an estimated $291K sold.

Man Group first reported a position in GTHX in Q3 2020 and held it in 7 quarters. The position peaked at $1.74M in Q4 2020. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Man Group reported no remaining G1 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Man Group sold 127,723 G1 Therapeutics shares in Q3 2024, an estimated $291K.
  • Man Group first reported a position in G1 Therapeutics in Q3 2020 and held it in 7 quarters.
  • Man Group's G1 Therapeutics position peaked at $1.74M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics as of Q3 2024.

Based on Man Group's 13F filing for Q3 2024, filed 14 Nov 2024.